Purpose. Methicillin-resistant Staphylococcus aureus (MRSA) is one of the leading causes of nosocomial infections. A thorough understanding of the epidemiology and distribution of MRSA allows the development of better preventive measures and helps to control or reduce the rate of infection among the general population.
INTRODUCTION
Antibiotics, routinely used to treat or prevent bacterial infections, are an essential component of modern medicine. Before the discovery of antibiotic agents, infections from common opportunistic pathogens such as Staphylococcus aureus had high mortality rates [1] . The discovery and clinical application of antibiotics in the early to mid-twentieth century brought optimism to the medical field regarding the successful treatment and prevention of bacterial infections. Unfortunately, the optimism was short lived due to the emergence of antibiotic-resistant bacterial strains, threatening our ability to treat common infectious diseases and necessitating the development of new classes of antibiotics to maintain drug efficacy against such pathogens. While new antibiotics can provide a temporary solution, they too are susceptible to the emergence of resistance profiles [2] , underlining the crucial role of continuous surveillance of antibiotic resistance in efforts to improve public health and clinical outcomes.
The evolutionary adaptation of micro-organisms' resistance to antibiotics should be considered a natural phenomenon resulting from adaptation to the selective pressure of antibiotics. Genetic malleability facilitates such adaptation by random mutation and the consequential outcome of each mutation with respect to the environment. Mutation rate leading to antibiotic resistance is the product of multifaceted interaction among many factors in a complex network of variables which determine the rate and type of mutants under selective pressure of antibiotics [3] . This matter is further complicated by the fact that a phenotype does not always reflect the genotype in all selected mutants due to mutations in different genes producing similar antibiotic-resistant phenotypes [3] . For instance, in mutations resulting in quinolone resistance, the rate of mutation is actually the result of the combination of the mutation rates of the genes that encode the synthesis of GyrA, GyrB, ParA and ParC [4, 5] .
Antibiotics target bacteria by various mechanisms that begin with the physical interaction between an antibiotic and its bacterial-specific target, resulting in alteration of bacterial physiology and ultimately inducing cell death or growth inhibition. At a subcellular level, the interaction of an antibiotic and its target may be through one or multiple pathways which may require one or multiple mutations to acquire resistance. Resistance mutation rates can be significantly altered for a given antibiotic depending on antibiotic concentration, proper use and/or misuse [6, 7] , and the antibiotic mode of action [8] . In some cases, antibiotics cannot reach their target molecule due to inhibition of transportation across the cell wall [9] , or by the activity of efflux pumps [10] . Quite often, the existence of alternative pathways may promote the resistance phenotype [9] . An example of this mode of resistance is the production of penicillin-binding protein 2a (PBP2a) in addition to the regular penicillin-binding proteins. PBP2a which has a low affinity for penicillin inducing the emergence of penicillin-resistant species [11, 12] . Alternatively, enzymatic activity within bacteria may also result in antibiotic degradation and ineffectiveness. An example of this mechanism is the function of beta-lactamases against penicillin. The bacterial enzymes cleave the four-membered beta-lactam rings, rendering the antibiotic inactive [9] .
Of notable study and particular importance in the area of antimicrobial resistance is the emergence of methicillinresistant Staphylococcus aureus (MRSA), a bacterium known for antibiotic resistance due to the mechanisms mentioned above. Methicillin is a narrow spectrum beta-lactam antibiotic belonging to the penicillin family and at one time, commonly used to treat infections from penicillinase-producing Gram-positive bacteria that were resistant to penicillin. Although methicillin use in medicine has been replaced by newer antibiotics, the name 'methicillin-resistant Staphylococcus aureus' has remained in use when referring to antibiotic-resistant staphylococcal infections. In current clinical practice, MRSA indicates resistance to oxacillin, an analogue of methicillin, or cefoxitin, a second-generation cephamycin [13] . Although evidence suggests the rate of severe MRSA infections in hospitals is falling in the United States [14] , the rate of community-acquired MRSA infections has consistently increased among the general population [15, 16] . This epidemiological shift in distribution of MRSA from healthcare-related facilities to the general population is alarming and emphasizes the importance of epidemiological research on antibiotic resistance [17] .
In current clinical practice, antimicrobial resistance screening, in addition to many other factors such as the source of infection [18] , the renal and hepatic functions [8] , and genetic variation [19] are considered prior to antibiotic selection. While clinical diagnosis and underlining illness play a central role in these decisions, the relationship between antibiotic resistance and patient demographics should also be considered. The objective of this study was to evaluate the rate of antibiotic resistance with respect to patient age, gender and location (outpatients, inpatients and nursing home residents) in order to identify variables which may improve the efficacy of current treatments and curtail the future rate of resistance.
RESULTS
Epidemiological characteristics and distribution of isolates Of the 511 clinical isolates included in the study, 318 isolates were from outpatient sources, 103 were from nursing homes and 90 were from inpatient sources. The number of isolates was similarly distributed among males and females, 250 and 261 respectively. No statistically significant differences in resistance pattern between males and females were noted. The rate of resistance from inpatient, outpatient and nursing home locations displayed a similar pattern of antibiotic resistance to each antibiotic (data not shown). The most common specimen source in order of occurrence was wound (n=374), upper and lower respiratory track (n=87), urine (n=30), eye (n=7), blood (n=5) and miscellaneous (n=8). The distributions of isolates are shown in Table 1 .
Distribution of isolates according to the antibiotic mode of action
The resistant pattern for three antibiotics' mode of action was determined. The pattern of resistance for ribosomal inhibitors displayed a high resistance percentage for 50s ribosomal subunit inhibitors, erythromycin and azithromycin, across all age classes; low resistance percentage for 30s ribosomal subunit inhibitors, gentamycin; tRNA inhibitor, tetracycline; ribosomal elongation factor G inhibitor, fusidic acid; and 50s ribosomal subunit inhibitors, chloramphenicol and linezolid (Fig. 1a) . The resistance percentage for cell wall synthesis inhibitors, penicillin, ampicillin, amoxicillin, oxacillin, cefazolin, cefoxitin, cefotaxime, cephalothin, cefazolin, chloramphenicol, ciprofloxacin and ceftriaxone, remained consistently high in all age classes, while vancomycin, a bactericidal peptidoglycan cross-linkage inhibitor, consistently had a low resistance percentage in all age classes (Fig. 1b) . The resistance percentage to DNA synthesis inhibitors, ciprofloxacin, norfloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacin, significantly increased as patient age increased. The increased resistance becomes apparent in mid 30s and consistently increased as the patients' age increased. Rifampin, a RNA synthesis inhibitor, did not display an age-dependent resistance pattern and maintained a low resistance percentage in all age classes (Fig. 1c) . No age-dependent resistance was found for the folate synthesis inhibitors, sulfamethoxazole/trimethoprim. When the data was evaluated with respect to the number of fluoroquinolone-resistant profiles and the number of antibiotics, there was a positive correlation between patient age and an increased resistance to a larger number of antibiotics in the fluoroquinolone family. This pattern is characterized by a low frequency of resistance to multiple fluoroquinolone antibiotics in younger age classes and a high frequency of resistant isolates to multiple fluoroquinolone antibiotics in older age classes (Fig. 1d ). The F, R 2 and significance (P) values for a linear regression for each antibiotic are shown in Table 2 .
Distribution of isolates according to antibiotic class
When the data was organized based on the antibiotic classification, fluoroquinolone resistance displayed a gradual but steady increase in aging patients (Fig. 2a) . This age-dependent pattern was absent in cephalosorins, penicillins and macrolides which consistently displayed a high resistance percentage in all age classes (Fig. 2b-d) . Other antibiotics such as rifampin, vancomycin, tetracycline and sulfamethoxazole-trimethoprim maintained a low resistance percentage across all age classes (Fig. 2e) .
DISCUSSION
Increasing prevalence of drug-resistant bacterial infections necessitates a better understanding of the multi-layered mechanisms by which antibiotic-resistant phenotypes develop. Antibiotic resistance can result from a single genomic mutation (independent mutations) [20] , or concomitant mutations in several genes (cooperative mutation) [3, [21] [22] [23] [24] . In either case, the genomic mutations are the consequence of errors during the replication process, followed by continuation of lineage by vertical transmission, and/or by horizontal gene transfer and acquiring the resistant genetic elements from unrelated species. Regardless of the mode of acquisition, in antibiotic-resistant strains, the mutations often maintain a muted expression until the selective Table 1 . Demographics and distribution of clinical isolates
MRSA isolates
Total n=511
Males n=250
Females n=261
Inpatients n=90
Outpatients n=318
Nursing homes n=103
Source of specimens Wound n=374
Respiratory track n=87
Urine n=30
Eye n=7
Blood n=5
Miscellaneous n=8 pressure of antibiotic consumption elicits the advantage of mutations [4, 24] . It is important to note that antibiotic resistance in a clinical context, as applied in this report, refers to the frequency at which detectable mutants arise in a bacterial population in the presence of a given antibiotic concentration [3] . Mutation rate in this framework refers to favourable mutations that lead to a visible antibiotic-resistant phenotype, and not the number of mutation events per cell, which may differ in organisms with the same antibiotic-resistant phenotype. For instance, quinolone resistance may be due to two types of chromosomal mutations either targeting DNA synthesis (i.e. DNA gyrase and topoisomerase) and/or increasing the expression of efflux pumps (i.e. norA) [5] .
Although it is difficult to assess what factors determine why some bacteria become resistant to one antibiotic but not others, the current report highlights the relationship between fluoroquinolone antibiotic resistance and patient age, in which, as the patient age increases, the rate of antibiotic resistance to fluoroquinolones also increases. This pattern was absent in other classes of antibiotics, such as penicillins or macrolides, which displayed either a high or low rate of antibiotic resistance irrespective of patient age. In addition, with respect to the fluoroquinolone family, as patient age increases, the number of multiple-resistant isolates also increases. This pattern is characterized by resistance to norfloxacin in the first decade of life, followed by increased resistance to ciprofloxacin, levofloxacin and ofloxacin in the fourth decade, and ultimately, by resistance to moxifloxacin and gatifloxacin at a later age, acquiring multiple resistances to all members of fluoroquinolone family.
Multiple studies have shown a relationship between fluoroquinolone resistance and patient age, primarily in Gramnegative species. Norfloxacin resistance was noted to be lowest in patients <15 years of age and to increase most sharply in patients >74 years of age for the treatment of Escherichia coli in urinary tract infections, with a strong gender relationship of males exhibiting higher rates of resistance at a younger age. In another study on E. coli, fluoroquinolone resistance associated with patient age and gender showed an increased probability of resistance by 1.027-fold for each year of age with males being significantly more likely to have resistant isolates than females [25] . A study on Haemophilus influenza showed fluoroquinolone-resistant strains starting in patients 58 years of age, with increasing resistance thereafter [26] . Older age has also been shown to be an independent risk factor for fluoroquinolone resistance in Klebsiella pneumoniae [27] . Although lower levels were reported, multiple studies have found fluoroquinolone resistance to be significantly higher in patients >64 years of age for the treatment of Gram-positive Streptococcus pneumoniae [28] [29] [30] . While in our study MRSA isolates exhibited no difference between male and female resistance patterns, our data provides further evidence that fluoroquinolone resistance with respect to patient age is not a species-specific occurrence.
Fluoroquinolones are antibacterial agents that target DNA gyrase subunits of topoisomerase II and parC and/or parE subunits of topoisomerase IV on chromosomal DNA [31] [32] [33] [34] [35] . DNA gyrase relieves the DNA supercoiling during replication of the DNA strands, while during cell division, topoisomerase IV separates the daughter strands prior to bacterial fission. Inhibition of either enzyme causes an interruption of the replication and transcription process, which in turn have either bactericidal or bacteriostatic effects [36] . In S. aureus, the parC gene acquires the initial mutation, leading to a low level of resistance with a MIC of 8 µg ml
À1
. The subsequent gyrA mutation in the following generations increases the resistance level to MIC!64 µg ml À1 [36] . Therefore, ineffective administration of antimicrobial Table 2 . Linear regression analysis
The ratio of the mean regression sum of squares divided by the mean error sum of squares (F), significance (P) and the coefficient of determination (R 2 ) values for simple regression for each antibiotic are depicted above (*P<.05, **P<.001). Abbreviations: amoxicillin clavulanate (AMC), ampicillin (AMP), ampicillin sulbactam (SAM), azithromycin (AZM), cefazolin (CFZ), cefotaxime (CTX), ceftriaxone (CRO), cephalothin (CEF), chloramphenicol (CHL), ciprofloxacin (CIP), erythromycin (ERY), fusidic acid (FOF), gatifloxacin (GAT), gentamicin (GEN), imipenem (IPM), levofloxacin (LVX), linezolid (LZD), moxifloxacin (MXF), norfloxacin (NOR), ofloxacin (OFX), oxacillin (OXA), penicillin (PEN), rifampicin (RIF), tetracycline (TET), sulfamethoxazole-trimethoprim (SXT), and vancomycin (VAN). agents, therapeutically or as prophylaxis, may introduce or select for mutations that may remain as a low resistance level within the normal flora, increasing the chance of higher resistance levels under the selective pressure of causative agents over generations. This disturbance in the ecological balance generates a favourable environment for acquisition of more resistant strains throughout patients' life span.
Antibiotics
The existence of multiple fluoroquinolone targets suggests a multi-step mechanism for the acquisition of a resistant phenotype. Low levels of fluoroquinolone resistance may be a product of single mutation in either DNA gyrases or topoisomerases, and once reduced sensitivity to the drug arises from the first mutation, higher levels of resistance may be reached from additional mutations [29, 37] . In such a cooperative mutation, which requires multiple mutations to gain a resistance phenotype, acquisition of a resistant phenotype would occur considerably less frequently than a single independent mutation. In this context, if there are several mutations which may independently result in antibiotic resistance, the mutation rate will be the sum of the independent mutation rate, while if two or more concomitant mutations are required for a resistance phenotype, the overall mutation will be the product of the independent mutation rates which will be a significantly smaller rate than the single mutation requirement [3] . This may account for the low resistance level among the younger population for fluoroquinolone class and higher resistance as patients age. In addition, others have demonstrated that bacteria have a capacity to acquire an increased mutation rate over time under selective environmental pressure [38] . Such hypermutable strains have the capacity of adapting to a succession of environmental bottle necks, and as a result, develop a large variability of alleles that can survive the stressful conditions, as the case may be for selection under antibiotic treatment [39, 40] . The requirements for cooperative mutation and the fact that many bacteria such as S. aureus naturally colonize the human body may account for the increased rate of resistance to fluoroquinolones with respect to patient age and the accumulation of mutations over time. It is also important to note that ineffective antibiotic treatment against a specific strain of pathogen may, in the long term, increase the emergence of resistant profiles for other species either by selecting for mutant strains and/or by horizontal gene transfer from unrelated resistant species. If this assumption holds true, for instance, ineffective antibiotic treatment for Streptococcus pneumoniae or E. coli, may raise the risk of subsequent emergence of other antibiotic-resistant strains, such as MRSA, by selecting for resistant mutations over the patients' life span.
Other mechanisms of resistance to fluoroquinolones may also occur through increased expression of genes such as norA, which codes for an efflux pump. Efflux pumps are localized at the cell membrane and reduce antibiotic efficacy by pumping the drug out of the cell, often resulting in a broad-spectrum resistance. Reports to date suggest an interaction between pump overexpression and the probability of obtaining additional mutations in subsequent generations as was demonstrated for levofloxacin [24] .
Although the most common problems with antibioticresistant strains do not have simple solutions, antibiotic selection from currently available candidates demands meticulous analyses of benefits and detriments associated with each antibiotic regiment in order to balance each against the others. Epidemiological analysis, such as the current report, can provide opportunities to better understand the microevolution of pathogens such as S. aureus. Factors such as bacterial and host population dynamics and patient demographics should be taken into consideration for effective short-or long-term antibacterial strategies to reduce the emergence of a resistant phenotype [34, 41] . The current report highlights the relationship between patient age and antibiotic resistance percentage for fluoroquinolones and emphasizes the need for better understanding of epidemiology and distribution of antibiotic resistance with respect to patient demographics. (3) outpatients: samples processed by ACMC emergency rooms and a local network of family practice physicians and/or clinics. All specimens were collected by healthcare professionals and transported to a hospital clinical microbiology laboratory. The diagnosis of MRSA infection was determined based on clinical laboratory culture findings for resistance to oxacillin. The diagnosis of MRSA infection was determined based on clinical laboratory culture findings for resistance to oxacillin, and specimens were divided based on patients' age into 10 age classes from younger to older (Table 3) . The MicroScan WalkAway 96 Plus system (Siemens, New York, NY) served as the primary reference method for bacterial identification and antibiotic screening tests. To prevent duplicate samples from the same patient, clinical samples from the same patient and from the same sample source that were collected/processed within a six-month period were counted as one occurrence. Data were analysed by using SAS 9.3 (SAS Institute, Cary, NC) and Excel (Microsoft, Redmond, WA). To study relationships between two continuous (quantitative) variable (patient age vs resistance percentage), a simple linear regression was calculated for each antibiotic to predict the antibiotic resistance percentage with respect to patient age. By placing patient age (independent variable) on the x-axis and the resistance percentage (dependent variable) on the y-axis, a scatter chart was generated. The F-value, which is the ratio of the mean regression sum of squares divided by the mean error sum of squares, and the coefficient of determination (R 2 ), which is a statistical measure of how close the data are to the fitted regression line, were calculated. F-value will range from zero to an arbitrarily large number and describes the probability that the null hypothesis for the model is true and the regression coefficients are zero. Since R 2 is the percent proportion, it is always a number between 0 and 1, with approaching closer to 0, suggesting less of the variability of the data explained by the regression line, and approaching 1 suggests the regression model explains the variability of the response data around its mean. In other words, the R 2 statistic provides a measure of how well the model is fitting the actual data, while F-distribution is a good indicator of whether there is a relationship between our predictor and the response variables. The results for the linear regression equation are shown in Table 2 . 
METHODS

